The FDA has granted orphan drug designation to Birchbiomed’s FS2 as a treatment for idiopathic pulmonary fibrosis, or IPF.

Bionews, Inc., the parent company of this site, has partnered with the following nonprofit advocacy organizations to help further the mission of ensuring that patients and caregivers are able to get ...

Columnist Samuel Kirton shares his emergency "go bag" checklist of things he brought when he received a bilateral lung ...

Researching IPF after her late husband's diagnosis meant learning many new acronyms and abbreviations, says guest writer.

Inhaled lipid nanoparticles loaded with two medicines reduced IPF lung stiffness and fibrosis in mice, outperforming an ...

As an organ recipient, columnist Sam Kirton honors donors and their families each year by decorating holiday trees in the ...

As my husband Donnie’s diagnosis of pulmonary fibrosis (PF) slowly unfolded, I found myself oscillating between anger, sorrow, and disbelief. At the time his symptoms appeared, he was only in his 30s.

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...